Drug Discovery and Development: New Options for Old Diseases
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (31 July 2022) | Viewed by 44738
Special Issue Editor
Interests: pharmacology of pain; inflammation; cancer; natural products
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Inflammatory or tumoral diseases have caused a significant increase in the number of cases each year. Chronic diseases, such as endometriosis, Crohn's syndrome, diabetic neuropathy, neuropathic pain, are some examples of conditions without specific treatment that are responsible for a large number of patients. In addition, they are also responsible for increasing leave from work. This causes damage to both companies and workers. Thus, the search for new molecules, both synthetic and of natural origin, that can be studied as potential treatments for the most diverse pathologies is urgent. In addition, drug repositioning is an interesting strategy that can lead to less costs in the process of discovering a new drug. Potential topics include, but are not limited to: New molecules for treating inflammatory diseases (i.e., endometriosis, inflammatory bowel disease); Search of new molecules for treating pain diseases (i.e., neurophatic pain); New molecules with antitumoral effects describing the possible mechanism of action; New molecules or isolated substances from natural origin in treating chronic diseases; Mechanisms of action describing the new molecules in vitro and/or in vivo disease models; Reporsitioning of old drugs in new possible treatments.
Dr. Patricia Dias Fernandes
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- endometriosis
- crohn disease
- inflammatory bowel disease
- neurophatic pain
- inflammation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.